CRNX

Crinetics Pharmaceuticals, Inc. [CRNX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CRNX Stock Summary

Top 10 Correlated ETFs

CRNX


Top 10 Correlated Stocks

CRNX


In the News

08:00 29 Sep 2023 CRNX

Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023

SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023.

09:11 29 Sep 2023 CRNX

Up 83% in 5 Days, Is Crinetics Pharmaceuticals a Buy?

Crinetics Pharmaceuticals' lead candidate could be commercialized soon. It'll have a hard time gaining market share quickly if it gets approved for sale.

08:37 29 Sep 2023 CRNX

Why Crinetics Pharmaceuticals Stock Soared This Week

Crinetics Pharmaceuticals announced positive late-stage trial data for its acromegaly drug this week. If approved, analysts think this oral therapy could rake in nearly half a billion in annual sales at peak.

12:57 29 Sep 2023 CRNX

Why Shares of Crinetics Pharmaceuticals Are Jumping Monday

Crinetics focuses on treatments for rare endocrine-related diseases and cancers. The company had only $264.5 million in cash as of the second quarter.

10:57 29 Sep 2023 CRNX

Pharma Stock Eyes Best Day Ever on Successful Trial

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock is surging today, last seen up 72.7% to trade at $27.58 at last check, after the late stage trial for its experimental drug paltusotine to treat a rare hormonal disorder was successful.

08:04 29 Sep 2023 CRNX

Why Is Crinetics Pharmaceuticals (CRNX) Stock Up 64% Today?

Crinetics Pharmaceuticals (NASDAQ: CRNX ) stock is on the rise Monday after the company announced positive clinical trial results. According to a press release from the company, its Phase 3 PATHFNDR-1 clinical trial was able to meet all of its primary and secondary endpoints.

08:01 29 Sep 2023 CRNX

Crinetics Pharmaceuticals shares surge 65%, analysts raise price target after acromegaly treatment results

Shares of Crinetics Pharmaceuticals Inc. CRNX, -1.18% gained 65% premarket on Monday after the company announced positive results from a late-stage study of paltusotine, its investigational treatment for acromegaly. The phase 3 trial met the primary endpoint and all secondary endpoints and no serious or severe adverse events were reported in patients receiving paltusotine for acromegaly, a rare disease that occurs when the body produces too much growth hormone.

08:06 29 Sep 2023 CRNX

Crinetics Pharmaceuticals shares rise as analysts see ‘drug hunters in their zone'

Shares of Crinetics Pharmaceuticals Inc. CRNX, gained more than 4% premarket on Thursday after Oppenheimer analysts initiated coverage of the shares with an outperform rating, calling Crinetics ‘drug hunters in their zone.' Crinetics focuses on developing treatments for rare endocrine diseaess, an area where current drugs' risk-benefit tradeoffs “leave much room for improvement, or approved options are outright lacking,” the analysts wrote in a note Wednesday.

06:07 29 Sep 2023 CRNX

Crinetics Pharmaceuticals: Creating Next-Generation Treatments In Acromegaly

Crinetics Pharmaceuticals, Inc. is my latest long position. The company has two Phase 3 data releases for Paltusotine in treating acromegaly over the next 7-8 months. Acromegaly is a disorder caused by excess levels of growth hormone, and current treatments have side effects.

03:43 29 Sep 2023 CRNX

Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At ENDO

Crinetics Pharmaceuticals has shown a significant increase in R&D and administrative expenses, leading to a widening net loss trajectory. The company's primary revenue source is the drug paltusotine, which has shown promising results in the treatment of acromegaly. Crinetics has a robust product pipeline, including potential treatments for Cushing's disease and neuroendocrine tumors.

CRNX Financial details

Company Rating
Neutral
Market Cap
1.91B
Income
-177.81M
Revenue
4.83M
Book val./share
4.68
Cash/share
4.87
Dividend
-
Dividend %
-
Employees
210
Optionable
No
Shortable
Yes
Earnings
13 Nov 2023
P/E
-8.56
Forward P/E
-
PEG
-4.58
P/S
383.45
P/B
5.99
P/C
6
P/FCF
-11.49
Quick Ratio
8.18
Current Ratio
8.73
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-3.3
EPS next Y
-
EPS next Q
-
EPS this Y
10.79%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
6.67%
Revenue last 5Y
14.3%
Revenue Q/Q
-63.12%
EPS Q/Q
14.63%
-
-
-
-
SMA20
70.59%
SMA50
45%
SMA100
38.1%
Inst Own
99.88%
Inst Trans
0.98%
ROA
-61%
ROE
223%
ROC
-0.74%
Gross Margin
100%
Oper. Margin
-3972%
Profit Margin
-3678%
Payout
-
Shs Outstand
66.13M
Shs Float
47.23M
-
-
-
-
Target Price
39.5
52W Range
15.23-31.0
52W High
-5.73%
52W Low
+94.83%
RSI
66
Rel Volume
0.66
Avg Volume
1.29M
Volume
858.63K
Perf Week
2.11%
Perf Month
80.29%
Perf Quarter
82.43%
Perf Half Y
83.46%
-
-
-
-
Beta
0.851659
-
-
Volatility
0.56%, 6.05%
Prev Close
4.26%
Price
29.225
Change
1.83%

CRNX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0.20.0500.030.09
Net income per share
-2.23-2.05-2.39-2.78-3.08
Operating cash flow per share
-1.6-1.92-2.04-2.3-2.22
Free cash flow per share
-1.69-1.94-2.04-2.32-2.25
Cash per share
13.54.95.618.686.43
Book value per share
-3.57-3.88-5.5-7.16-8.45
Tangible book value per share
13.24.855.558.646.09
Share holders equity per share
-3.57-3.88-5.5-7.16-8.45
Interest debt per share
00.20.130.080.12
Market cap
364.14M606.55M429.62M1.09B951.27M
Enterprise value
319.17M571.07M340.55M894.35M920.62M
P/E ratio
-13.43-12.24-5.9-10.23-5.95
Price to sales ratio
149.97508.426.05K1.01K200.82
POCF ratio
-18.71-13.08-6.93-12.33-8.26
PFCF ratio
-17.75-12.94-6.91-12.27-8.14
P/B Ratio
-8.39-6.47-2.56-3.97-2.17
PTB ratio
-8.39-6.47-2.56-3.97-2.17
EV to sales
131.45478.694.8K829.63194.35
Enterprise value over EBITDA
-11.12-10.61-4.54-8.3-5.48
EV to operating cash flow
-16.4-12.31-5.49-10.1-7.99
EV to free cash flow
-15.56-12.18-5.47-10.05-7.88
Earnings yield
-0.07-0.08-0.17-0.1-0.17
Free cash flow yield
-0.06-0.08-0.14-0.08-0.12
Debt to equity
0-0.05-0.02-0.010
Debt to assets
00.040.020.010.01
Net debt to EBITDA
1.570.661.191.830.18
Current ratio
21.0314.7916.9221.5512.45
Interest coverage
0000-38.89
Income quality
0.720.920.840.820.7
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.7411.33253.8922.758.95
Research and developement to revenue
10.0834.79802.7978.1627.49
Intangibles to total assets
00000
Capex to operating cash flow
0.050.01000.01
Capex to revenue
-0.44-0.41-2.62-0.4-0.35
Capex to depreciation
-2.25-0.55-0.2-0.47-1.68
Stock based compensation to revenue
0.965.28146.8616.15.97
Graham number
13.413.3717.2221.1524.19
ROIC
0.70.630.460.40.38
Return on tangible assets
-0.16-0.38-0.4-0.3-0.45
Graham Net
12.674.365.158.335.78
Working capital
158.76M115M167M328.73M317.46M
Tangible asset value
160.23M117.14M168.92M331.94M316.33M
Net current asset value
155.49M110.1M162.97M325.65M309.34M
Invested capital
0-0.05-0.02-0.010
Average receivables
1.16M1.48M1.61M1.93M2.23M
Average payables
929.5K3.48M5.54M7.03M7.68M
Average inventory
70.5K-689K-1.61M3.12M4.04M
Days sales outstanding
238.12421.69.42K687186.85
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
1.530.870.040.531.95
Payables turnover
00000
Inventory turnover
00000
ROE
0.630.530.430.390.36
Capex per share
-0.09-0.02-0.01-0.01-0.03

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
0.010.010.010.050.02
Net income per share
-0.79-0.75-0.79-0.82-0.94
Operating cash flow per share
-0.53-0.72-0.65-0.76-0.84
Free cash flow per share
-0.54-0.73-0.66-0.76-0.85
Cash per share
7.786.856.215.494.87
Book value per share
7.356.53-8.16-94.68
Tangible book value per share
7.356.535.885.24.68
Share holders equity per share
7.356.53-8.16-94.68
Interest debt per share
0.060.090.070.020.05
Market cap
979.54M1.06B985.25M865.76M978.04M
Enterprise value
919.81M1.03B954.61M827.39M941.05M
P/E ratio
-5.87-6.54-5.81-4.92-4.8
Price to sales ratio
2.23K2.31K1.39K323.17989.91
POCF ratio
-35.01-27.44-27.98-21.26-21.38
PFCF ratio
-34.26-26.97-27.77-21.25-21.27
P/B Ratio
2.543.01-2.24-1.783.85
PTB ratio
2.543.01-2.24-1.783.85
EV to sales
2.1K2.25K1.35K308.84952.48
Enterprise value over EBITDA
-21.46-23.8-20.07-17.25-17.85
EV to operating cash flow
-32.88-26.73-27.11-20.32-20.58
EV to free cash flow
-32.17-26.26-26.9-20.31-20.47
Earnings yield
-0.04-0.04-0.04-0.05-0.05
Free cash flow yield
-0.03-0.04-0.04-0.05-0.05
Debt to equity
0.010.010-0.010.01
Debt to assets
0.010.010.010.010.01
Net debt to EBITDA
1.390.640.640.80.7
Current ratio
15.9415.4112.4511.68.73
Interest coverage
-59.78-28.97-24.9824.190
Income quality
0.660.920.780.890.9
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
23.8926.0415.94.5513.51
Research and developement to revenue
75.1669.8452.1714.3641.13
Intangibles to total assets
00000
Capex to operating cash flow
0.020.020.0100.01
Capex to revenue
-1.4-1.49-0.39-0.01-0.24
Capex to depreciation
-2.85-2.75-0.98-0.06-0.85
Stock based compensation to revenue
16.2416.2311.213.0210.3
Graham number
11.4610.5112.0312.869.95
ROIC
-0.11-0.120.10.1-0.2
Return on tangible assets
-0.1-0.1-0.12-0.14-0.17
Graham Net
7.176.325.584.884.33
Working capital
390.17M353.77M317.46M279.08M252.2M
Tangible asset value
386.17M351.37M316.33M280.33M254.12M
Net current asset value
380.72M344.82M309.34M271.72M245.67M
Invested capital
0.010.010-0.010.01
Average receivables
1.83M2.23M2.39M2.39M2.37M
Average payables
10.59M7.46M6.38M6.39M5.37M
Average inventory
4.7M5M2.98M-1.17M6.39M
Days sales outstanding
432.78460.81307.8378.91216.98
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.210.20.291.140.41
Payables turnover
00000
Inventory turnover
00000
ROE
-0.11-0.110.10.09-0.2
Capex per share
-0.01-0.01-0.0100

CRNX Frequently Asked Questions

What is Crinetics Pharmaceuticals, Inc. stock symbol ?

Crinetics Pharmaceuticals, Inc. is a US stock , located in San diego of Ca and trading under the symbol CRNX

Is Crinetics Pharmaceuticals, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $39.5. The lowest prediction is $39 and the highest is $40

What is CRNX stock prediction ?

With a median analyst target price of $40, 1 stock analysts have made 1 forecasts in last 90 days. $40 is the lowest and $40 is the greatest projection.

What is Crinetics Pharmaceuticals, Inc. stock quote today ?

Crinetics Pharmaceuticals, Inc. stock price is $29.225 today.

Is Crinetics Pharmaceuticals, Inc. stock public?

Yes, Crinetics Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap